Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 春立医疗
Other Market Stock Code688236
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameChunli Medical
Stock Code01858
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一間專注於研發、生產及銷售植入性骨科醫療器械且信譽良好的中國骨科醫療器械公司,產品包括關節假體產品及脊柱產品。我們的關節假體產品包括髖關節假體、膝關節假體、肩關節假體及肘關節假體產品。我們的脊柱產品為脊柱內固定系統的全系列產品組合,包括頸椎前後路固定系統、胸椎固定系統及腰椎固定系統。
Listing Date2015-03-11
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市通州區通州經濟開發區南區鑫覓西二路10號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.clzd.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 13.88 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2015-02-27 to 2015-03-04
Global Offering Shares16,670,000 shares
HK Public Offer Shares (Initial)1,667,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)15,003,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO66,670,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 231,379,600

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 953M
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣32.7百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201120122013-0920132014-09
Revenue 80,26098,09572,652110,54691,346
Cost of sales -19,747-27,536-20,998-30,471-24,441
Gross profit 60,51370,55951,65480,07566,905
Selling and distribution expenses -13,022-16,344-14,878-20,145-19,341
Administrative expenses -11,316-16,131-14,034-20,581-19,273
Operating profit 34,71735,96820,43837,70925,785
Profit before tax 35,41037,20320,84738,11626,138
Income tax expense -5,005-5,263-2,955-5,451-3,469
Profit for the year 30,40531,94017,89232,66522,669
Balance Sheet
Item 2011201220132014-092015-01
Cash and cash equivalents 44,73061,25865,85646,82849,787
Trade and bills receivables 23,95830,65433,65354,26052,119
Inventories 17,77519,58723,08130,53038,199
Total current assets 96,618120,663132,704145,309162,269
Total assets 158,764187,510200,633218,181239,739
Total current liabilities 11,48014,34015,07018,96722,524
Total liabilities 11,48020,28620,74426,62330,111
Total equity 147,284167,224179,889191,558209,628
Cash Flow Statement
Item 201120122013-0920132014-09
Net cash from operating activities 32,46328,828-11,26628,202304
Net cash from investing activities -47,594-299-13,125-1,241-4,042
Net cash from financing activities -2,000-12,000-2,364-22,364-15,290
Net increase in cash -17,13116,529-26,7554,597-19,028
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 14.3
First Day OpenHK$ 14.08
First Day Change3.03%
First Day Volume10167800.0
First Day Turnover148959000.0
Use of Proceeds
1、全球發售所得款項凈額約50.0%或約97.5百萬港元將用于發展大興新生產基地第一期,包括: 1、1 約20.0%或約39百萬港元用作興建新生產廠房及配套設施; 1、2 約30.0%或約58.5百萬港元用作就標準關節假體、先進個性化關節假體及脊柱產品之生產而購置及安裝生產設備及機器。當新生產線開始運作(目前預計將為2017年10月前后),我們的標準假體、先進個性化關節假體及脊柱產品最大設計年產能將分別增加約40,000套、5,000套及25,000套; 2、全球發售所得款項凈額約20.2%或約39.39百萬港元將用于研發活動,包括: 2、1 約12.0%或約23.4百萬港元用作發展大興新生產基地之研發中心; 2、2 約4.2%或約8.19百萬港元用作購置新的研發設施及設備; 2、3 約4.0%或7.8百萬港元用作擴大我們就開發新產品及改善產品之研發活動之范疇; 3、全球發售所得款項凈額約20.0%或約39百萬港元將用于擴闊我們的現有營銷及經銷網絡以提升我們的市場滲透范圍至涵蓋更多經銷商及醫院,并因而增加我們的市場份額,包括: 3、1 約8.5%或約16.575百萬港元用作于大興新生產基地及中國其他地區建立及發展營銷服務中心,以擴闊我們營銷服務的地域覆蓋范圍; 3、2 約6.0%或11.7百萬港元用作招聘負責營銷之員工,以鞏固我們與醫院及醫療機構之關系及加強醫療執業人員對我們產品的認識; 3、3 約5.5%或10.725百萬港元用作贊助并參與學術會議及研討會; 4、全球發售所得款項凈額約9.8%或約19.11百萬港元將用于營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
CHINA EVERBRIGHT CAPITAL LIMITED CE ACE409
Overall Coordinators (1)
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Bookrunners (1)
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Lead Managers (1)
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman史春寶—
Company Secretary丁罡、葉沛森—
No director data available.

Major Shareholders

Major Shareholders & Holdings史春寶先生及岳術俊女士為控股股東,截至最後實際可行日期分別持有24,237,087股及18,762,913股內資股,佔已發行股本約48.5%及37.6%;緊隨全球發售完成後(假設超額配股權未獲行使)分別持有約36.4%及28.1%,合共約64.5%。
About this page

This page shows Chunli Medical (01858) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect